Search

Your search keyword '"Volpato, Maria C."' showing total 10 results
Start Over Author "Volpato, Maria C."
10 results on '"Volpato, Maria C."'

3. Complexation of oxethazaine with 2-hydroxypropyl-β-cyclodextrin: increased drug solubility, decreased cytotoxicity and analgesia at inflamed tissues

Author

Prado, Andressa R, primary, Yokaichiya, Fabiano, additional, Franco, Margareth Kazuyo Kobayashi Dias, additional, Morais Gonçalves da Silva, Camila, additional, Oliveira-Nascimento, Laura, additional, Franz-Montan, Michelle, additional, Volpato, Maria C, additional, Cabeça, Luís F, additional, and de Paula, Eneida, additional

Published
2017
Full Text
View/download PDF

5. Micro and nanosystems for delivering local anesthetics

Author

de Paula, Eneida, primary, Cereda, Cíntia MS, additional, Fraceto, Leonardo F, additional, de Araújo, Daniele R, additional, Franz-Montan, Michelle, additional, Tofoli, Giovana R, additional, Ranali, José, additional, Volpato, Maria C, additional, and Groppo, Francisco C, additional

Published
2012
Full Text
View/download PDF

10. Efficacy of liposome-encapsulated mepivacaine for infiltrative anesthesia in volunteers.

Author

Tofoli, Giovana R., Cereda, Cíntia M.S., Groppo, Francisco C., Volpato, Maria C., Franz-Montan, Michelle, Ranali, José, de Araújo, Daniele Ribeiro, and de Paula, Eneida

Subjects
DRUG efficacy, LOCAL anesthetics, LIPOSOMES, MICROENCAPSULATION, ANESTHESIA, PAIN, ADRENALINE
Abstract

This blinded crossover study evaluated the efficacy and pain sensitivity evoked by a previously reported liposome-encapsulated mepivacaine formulation (Araujo et al., 2004). Thirty healthy volunteers received an intraoral injection (1.8 mL), at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine (MVC2%EPI), 3% mepivacaine (MVC3%), and 2 and 3% liposome-encapsulated mepivacaine (MVC2%LUV and MVC3%LUV). Latency period and duration of anesthesia were assessed by an electrical pulp tester and injection discomfort by a visual analog scale (VAS). Data were analyzed with Tukey-Kramer and Friedman tests ( P < 0.05). No significant difference was found regarding latency period (in minutes) among the formulations ( P > 0.05). The duration of anesthesia after the injection of MVC3%LUV was higher than the one obtained after the infiltration of MVC2%LUV and of MVC3% ( P < 0.05). However, the duration of anesthesia obtained with MVC3% did not differ from the one obtained with MVC2%LUV ( P > 0.05). MVC3%LUV showed lower VAS median values than MVC2%EPI ( P < 0.05), and there were no significant differences among the others formulations. Liposome-encapsulated 3% mepivacaine showed longer duration of anesthesia, in comparison to the commercial formulation of MVC3%. MVC2%LUV was able to produce a similar duration of anesthesia as the 3% commercial formulation, despite the 50% decrease in the anesthetic concentration. Thus, the encapsulation of mepivacaine increased the duration of anesthesia and reduced the injection discomfort caused by vasoconstrictor-associated formulations in healthy volunteers. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results